logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: disease
Load new posts () and activity
Like Reblog Comment
show activity (+)
review 2018-07-12 14:29
Review: “Boystown 4: A Time For Secrets” (Boystown Mysteries, #4) by Marshall Thornton
Boystown 4: A Time For Secrets - Marshall Thornton

 

~ 4 stars ~

 

Like Reblog Comment
show activity (+)
review 2018-07-10 18:40
Review: “Boystown 3: Two Nick Nowak Novellas” (Boystown Mysteries, #3) by Marshall Thornton
Boystown 3: Two Nick Nowak Novellas - Marshall Thornton

 

~ 4 stars ~

 

Like Reblog Comment
text 2018-05-30 13:21
Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Clostridium difficile is a bacterium which infects the bowel and caused diarrhea. This infection is most commonly seen in people who were recently been treated with antibiotics and it can be spread easily to others. Clostridium difficile is also called as C. difficile or C.diff. C.diff infections may cause serious bowel problems. Symptoms of C.diff infections includes watery diarrhea, painful cramps in tummy, dehydration, dry mouth, head ache, loss of weight and appetite etc.

C.diff can be diagnosed by enzyme immunoassay, polymerase chain reaction, GDH or EIA. Treatment for Clostridium difficile infection includes antibiotics course.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By Trial Phase, Clostridium difficile Infections pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Clostridium difficile Infections pipeline drugs are segmented as:

  • SyntheticBiologics
  • Da Volterra
  • Pfizer Inc.
  • Valneva SE
  • Seres Therapeutics
  • Summit Therapeutics
  • Rebiotix Inc.
  • CRESTOVO
  • Merck
  • XBiotech
  • Others

By Drugs, Clostridium difficile Infections pipeline drugs are segmented as:

  • Vancomycin
  • Fidaxomicin
  • Metronidazole
  • Ridinilazole
  • Cadazolid
  • Bezlotoxumab
  • Others

 

By Type of Condition Clostridium difficile Infections pipeline drugs are segmented as:

  • Systemic JIA
  • Oligoarthritis
  • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
  • Psoriatic arthritis
  • Enthesitis-related arthritis
  • Undifferentiated arthritis

By Route of Administration, Clostridium difficile Infections pipeline drugs are segmented as:

  • Oral
  • Parenteral

 To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

Space Analysis:

  • In July 2016, Valneva SE completed Phase II study for its prophylactic vaccine candidate VLA84 targeting primary prevention of difficile infection (CDI). The study met its primary endpoint in terms of identifying the dose/formulation with the highest seroconversion rate against both toxins A and B and confirmed the favorable safety profile observed in Phase
  • In June 2017, Seres Therapeutics, Inc. initiated Phase 3 clinical study of its SER-109 (ECOSPOR III) in patients with multiply recurrent difficile infection and also commenced Phase 1b clinical trial evaluating SER-262 in patients with primary Clostridium difficile infection (CDI).
  • On May 11, 2017 The U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation for SYN-004 (ribaxamase) of Synthetic Biologicsfor the prevention of Clostridium difficile infection.
  • In October 2015, RBX2660 of Rebiotix was grated orphan drug status and fast track designation from U.S.FDA for its potential to prevent recurrent C. diff. infection.

 

Report Description:

Clostridium difficile InfectionsDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Clostridium difficile Infections treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Clostridium difficile Infections disease pipeline drugs development. This report studies the dynamics of the Clostridium difficile Infections Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Clostridium difficile Infections disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/clostridium-difficile-infectionsdisease-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

 

Like Reblog Comment
text 2018-05-30 12:21
Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Celiac Disease Pipeline Drugs Assessment

 

Overview:

Celiac Diseaseis a genetic autoimmune disease. It is caused due to the consumption of protein called gluten, which is found in barley, wheat,and rye. It enables damage the finger-like villi of small intestine and body will be unable to absorb nutrients into thebloodstream that leads to malnutrition. Symptoms of celiac disease include food allergy, watery and itchy eyes, difficulty in breathing, nausea, abdominal pain, mouth ulcers.

Celiac disease is diagnosed by serology tests and genetic tests. Treatment includes strict gluten-free diet. There are no FDA approved drugs to treat celiac disease.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

 

Segmentation:

By Drugs, Celiac Disease pipeline drugs are segmented as:

  • Larazotide
  • Pancrelipase
  • Rifaximin
  • Triamcinolone
  • Bupivacaine

By Route of Administration, Celiac Disease pipeline drugs are segmented as:

  • Oral
  • Parenteral

By Trial Phase, Celiac Diseasepipeline drugs are segmented as:

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Celiac Diseasepipeline drugs are segmented as:

  • AMYRA Biotech AG (Switzerland)
  • Avaxia Biologics, Inc. (U.S.)
  • Calypso Biotech SA (Switzerland)
  • Provid Pharmaceuticals Inc. (U.S.)
  • Sitari Pharmaceuticals (U.S.)
  • Cour Pharmaceuticals (U.S.)
  • Glenmark Pharmaceuticals Ltd. (India)
  • Innovate Biopharmaceuticals (U.S.)
  • Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

 

 

 

Space Analysis:

  • In November 2017, ImmusanT, Inc.raised $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners to proceedPhase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen DQ2.5 (HLA-DQ2.5) immune recognition gene.
  • In February 2016, Innovate Biopharmaceuticals Inc., completed an agreement to license Alba Therapeutics assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.
  • In December 2015, Takeda Pharmaceutical Company Limited and Cour Pharmaceutical Development Company, Inc. entered into a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease
  • In March 2015, Falk Pharma and Zedira entered into a collaboration to perform Phase 1 clinical trials of ED1227, a direct-acting inhibitor of tissue transglutaminase. The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the celiac disease process.

 

Report Description:

Celiac Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Celiac Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Celiac Disease pipeline drugs development. This report studies the dynamics of the Celiac Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Celiac Disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

 

 

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on each drug candidates in the clinical trial phases

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

 

Like Reblog Comment
text 2018-05-30 07:42
Batten Disease Treatment: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Batten Disease Treatment: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

 

Batten disease treatment market: Batten disease is most common group of disorders called Neuronal Ceroid Lipofuscinoses (NCLs). Batten disease is a rare, fatal and inherited nervous system disorder that generally begins in childhood. It is also caused by lysosome shortage. The symptoms in initial stages will be vision loss in previously healthy children followed by slow learning, personality and behavioural changes. Commonly within 2-4 years of vision loss seizures may appear. Generally, neuronal ceroid lipofuscinoses are classified into infantile NCL (INCL), late infant NCL (LINCL), juvenile NCL (JNCL) and adult NCL.

Market Outline: Global Batten disease Treatment

Batten disease treatment market is driven by an increase in R&D activities for development of new treatments for batten disease. In addition, lack of effective treatment options and increase in prevalence rates of batten disease treatment market are expected to boost the market growth over the forecast period. Furthermore, recent drug launches and growing awareness related to symptoms of disease are anticipated to bolster the batten disease treatment market during the forecast period. However, high cost of drug development, unavailability of many treatments for batten disease and a low number of patients are expected to hamper the market growth over the forecast period.

 

   A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

 

Global Batten disease Treatment market is segmented based on type of disease, treatment and distribution channel

 

Based on type of disease, batten disease treatment is segmented into

 

  • Juvenile NCL (JNCL)
  • Infantile NCL (INCL)
  • Late infant NCL (LINCL)
  • Adult NCL
  • Others

 

Based on treatment, batten disease treatment market is segmented into

 

  • Gene Therapy
  • Drug Therapy
  • Enzyme Therapy
  • Others

 

Based on distribution channel, batten disease treatment market is segmented into

 

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

 

 

 To view TOC of this report is available upon request @

 

 https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/#ulp-c654SbFYO64MsOhu

 

According to National Institute of Neurological Disorders and Stroke, Batten disease occurs in an estimated 2 to 4 of every 100,000 live birth in U.S., and it is more common in Sweden, Finland, other parts of Northern Europe, and Newfoundland, Canada. Batten disease treatment market is still in development stage. Companies are adopting licencing and collaborations to increase market share. For instance, In June 2015, Abeona Therapeutics, Inc. (formerly  PlasmaTech Biopharmaceuticals, Inc.) got worldwide exclusive rights to an AAV gene therapy for treatment of juvenile batten disease fromUNeMed Corporation, a technology transfer company. In addition, many of the research and educational institutions focused on the development of new treatments for batten disease. Furthermore, government and non-government organizations such as Batten Disease Support and Research Association, Beyond The Batten Disease Foundation and others are actively participating in increasing the awareness about the batten disease and further expected to boost the growth of market.

 

Geographically, batten disease treatment market has been segmented into Latin America, Europe, Asia-Pacific, North America, and the Middle East & Africa. North America and Europe batten disease treatment market growth is attributed to increasing in R&D expenditure, growing awareness related to the batten disease due to various awareness programs being taken by the non-government and government organizations in the region. Furthermore, well-established infrastructure and recent drug launches are expected to boost the market in the U.S. region. Asia Pacific region market is expected to offer lucrative growth due to lower R&D costs, developing healthcare infrastructure and growing prevalence rates of genetic disorders.

 

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

Some of the players in batten disease treatment market are Abeona Therapeutics Inc. (U.S.), BioMarin Pharmaceutical Inc. (U.S.), CereSpir Inc. (U.S.), Evotec AG (Germany), Ionis Pharmaceuticals Inc. (U.S.), Mitochon Pharmaceuticals Inc. (U.S.), and Spark Therapeutics Inc. (U.S.) to name a few.

 

  • In April 2017, U.S. FDA has approved BioMarin Pharmaceutical Inc.’s Brineura, the first FDA approved treatment for a form of batten disease.

 

 

Key Features of the Report

 

 

  • The report provides granular level information about The market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about The competitor’s overview, key findings and Their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by The industry
  • The report tracks recent innovations, key developments and startup’s details that are working in The industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

 

 

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/batten-disease-treatment-market/

 

About Precision Business Insights

 

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

 

Contact to Precision Business Insights,

 

Kemp House,

152 – 160 City Road,

London EC1V 2NX

 

Email: sales@precisionbusinessinsights.com

 

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

 

More posts
Your Dashboard view:
Need help?